China Approvals Rise But Conditional-To-Full Conversion Slips

Oncology Still Top For Drugs, Biologics

 
• By Xu Hu
  
Annual review
China's Central for Drug Evaluation recently published the annual report of drug review over the past year in 2024. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from China

More from Pink Sheet